Why the study?
Reporting ARVC, DCM, and HCM variants as secondary genomic findings allows early diagnosis but causes uncertainty due to incomplete penetrance, prompting evaluation of their prevalence and expression in the general population.
Does the presence of pathogenic or likely pathogenic variants for inherited cardiomyopathies increase the risk of cardiomyopathy, heart failure, or cardiovascular mortality in the general population?
Does the presence of pathogenic or likely pathogenic variants for inherited cardiomyopathies increase the risk of cardiomyopathy, heart failure, or cardiovascular mortality in the general population?
Pathogenic variants for inherited cardiomyopathies are relatively common in the general population and are associated with increased cardiovascular morbidity and mortality, but their overall disease penetrance is low, suggesting incidental findings should be interpreted cautiously.
May increase cardiomyopathy risk yet low penetrance cautions against overinterpreting incidental findings; leaves open optimal population screening and counseling strategies.
Background Pathogenic and likely pathogenic variants associated with arrhythmogenic right ventricular cardiomyopathy (ARVC), dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are recommended to be reported as secondary findings in genome sequencing studies. This provides opportunities for early diagnosis, but also fuels uncertainty in variant carriers (G+), since disease penetrance is incomplete. We assessed the prevalence and disease expression of G+ in the general population. Methods We identified pathogenic and likely pathogenic variants associated with ARVC, DCM and/or HCM in 200,643 UK Biobank individuals, who underwent whole exome sequencing. We calculated the prevalence of G+ and analysed the frequency of cardiomyopathy/heart failure diagnosis. In undiagnosed individuals, we analysed early signs of disease expression using available electrocardiography and cardiac magnetic resonance imaging data. Results We found a prevalence of 1:578, 1:251 and 1:149 for pathogenic and likely pathogenic variants associated with ARVC, DCM and HCM respectively. Compared to controls, cardiovascular mortality was higher in DCM G+ (OR 1.67 [95% CI 1.04;2.59], p=0.030), but similar in ARVC and HCM G+ (p≥0.100). Cardiomyopathy or heart failure diagnosis were more frequent in DCM G+ (OR 3.66 [95% CI 2.24;5.81], p=4.9×10 −7 ) and HCM G+ (OR 3.03 [95% CI 1.98;4.56], p=5.8×10 −7 ), but comparable in ARVC G+ (p=0.172). In contrast, ARVC G+ had more ventricular arrhythmias (p=3.3×10 −4 ). In undiagnosed individuals, left ventricular ejection fraction was reduced in DCM G+ (p=0.009). Conclusions In the general population, pathogenic and likely pathogenic variants associated with ARVC, DCM or HCM are not uncommon. Although G+ have increased mortality and morbidity, disease penetrance in these carriers from the general population remains low (1.2-3.1%). Follow-up decisions in case of incidental findings should not be based solely on a variant, but on multiple factors, including family history and disease expression.
No takes yet. Share an insight, caveat, or question.
Bourfiss et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: